ArticlebioRxiv : the preprint server for biology2025
CellFuse Enables Multi-modal Integration of Single-cell and Spatial Proteomics data.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Single-cell and spatial proteomic technologies capture complementary biological information, yet no single platform can measure all modalities within the same cell. Most existing integration methods are optimized for transcriptomic data and rely on a large set of shared, strongly linked features, an assumption that often fails for low-dimensional proteomic modalities. We present CellFuse, a deep learning-based, modality-agnostic integration framework designed specifically for settings with limited feature overlap. CellFuse leverages supervised contrastive learning to learn a shared embedding space, enabling accurate cell type prediction and seamless integration across modalities and experimental conditions. Across a range of datasets including healthy PBMCs, bone marrow, CAR-T-treated lymphoma, and healthy and tumor tissues-CellFuse consistently outperforms existing methods in both integration quality and runtime efficiency. It maintains high accuracy even in the presence of missing markers and rare cell types, and performs robustly in cross-dataset comparisons, making it a powerful tool for scalable and high-fidelity single-cell data integration in basic and translational research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.